The Majority of Surveyed U.S. Neurologists Selected Tysabri as the Most Effective Therapy for the Treatment of Relapsing-Remitting Multiple Sclerosis

BURLINGTON, Mass.–(BUSINESS WIRE)– Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the majority of surveyed U.S. neurologists (63 percent) selected Biogen Idec/Elan’s Tysabri as the most effective therapy for the treatment of relapsing-remitting multiple sclerosis, when compared to other currently available agents. However, no surveyed managed care organizations’ (MCO) pharmacy directors chose Tysabri as the most efficacious available agent for the indication.

Decision Resources’ analysis of the multiple sclerosis drug market reveals that surveyed neurologists’ overwhelming response is consistent with the perception among interviewed experts that Tysabri is the most effective therapy for relapsing-remitting multiple sclerosis—a view supported by clinical studies and clinical experience that suggest the drug’s efficacy is superior to other current agents. Surveyed neurologists indicate a high level of satisfaction with Tysabri’s efficacy, more specifically its impact on relapses (which is sizable compared with other current therapies), disability progression and lesions.